Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Mallinckrodt
Moodys
Baxter
Dow

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Concordia Company Profile

See Plans and Pricing

« Back to Dashboard

Summary for Concordia
International Patents:9
US Patents:1
Tradenames:16
Ingredients:14
NDAs:15
Patent Litigation for Concordia: See patent lawsuits for Concordia

Drugs and US Patents for Concordia

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Concordia SALAGEN pilocarpine hydrochloride TABLET;ORAL 020237-002 Apr 18, 2003 AB RX Yes Yes   Start Trial   Start Trial
Concordia LANOXIN digoxin TABLET;ORAL 020405-003 Sep 30, 1997 DISCN Yes No   Start Trial   Start Trial
Concordia PANRETIN alitretinoin GEL;TOPICAL 020886-001 Feb 2, 1999 RX Yes Yes   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Concordia

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 6,024,981   Start Trial
Concordia Pharms Inc KAPVAY clonidine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022331-003 Sep 28, 2010 5,869,100   Start Trial
Concordia Pharms Inc JENLOGA clonidine hydrochloride TABLET, EXTENDED RELEASE;ORAL 022331-002 May 25, 2010 5,869,100   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for CONCORDIA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Orally Disintegrating Tablets 10 mg, 15 mg and 30 mg ➤ Subscribe 2010-07-22
➤ Subscribe Extended-release Tablets 0.1 mg and 0.2 mg ➤ Subscribe 2011-03-04
➤ Subscribe Extended-release Tablets 10 mg ➤ Subscribe 2007-06-12
➤ Subscribe Extended-release Tablets 0.1 mg and 0.2 mg ➤ Subscribe 2011-03-04

Supplementary Protection Certificates for Concordia Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2822954 LUC00083 Luxembourg   Start Trial PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625
0579826 SPC/GB02/042 United Kingdom   Start Trial PRODUCT NAME: ERTAPENEM ((1R,5S,6S,8R,2'S,4'S)-2-(2-(3-CARBOXYPHENYLCARBAMOYL)PYRROLIDIN-4-YLTHIO)-6-(1-HYDROXYETHYL)-1-METHYLCARBAPENEM-3-CARBOXYLIC ACID), A PHARMACEUTICALLY ACCEPTABLE SALT OR IN VIVO HYDROLYSABLE ESTER THEREOF, ESPECIALLY AS THE MONOSODIUM SALT ERTA; REGISTERED: UK EU/1/02/216/001 20020422
2822954 1890030-8 Sweden   Start Trial PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; REG. NO/DATE: EU/1/18/1289 20180625
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
McKinsey
Colorcon
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.